Skip Navigation

AIDSInfo logo

 
Home > Drugs > SPL7013

SPL7013

Brand Name: VivaGel  Audio
Drug Class: Microbicides
SPL7013, also known as VivaGel, is a type of medicine called a microbicide. Microbicides are substances that protect the body from infection by microorganisms such as bacteria, viruses, and fungi. Microbicides work by either destroying the microbes or preventing them from establishing an infection.

HIV/AIDS-Related Uses
SPL7013 is an investigational medicine that is not yet approved by the FDA for use outside of clinical trials. It is being studied for the prevention of HIV infection. SPL7013 is also being studied for the prevention of other sexually transmitted infections including herpes simplex virus-2 (HSV-2), the virus that causes genital herpes.
This medicine does not cure HIV infection or AIDS and is being studied to reduce the risk of passing the virus to other people.

Dosage Form/Administration
SPL7013 comes in gel form and is applied vaginally with a single-use, prefilled vaginal applicator.

Recommended Daily Dose
SPL7013 has been given once or twice a day, every day, for up to 2 weeks in safety, tolerability, and acceptability studies. A 3% preparation of SPL7013 has been and is currently being evaluated in clinical trials.

Contraindications
Individuals should tell a doctor about any medical problems before taking this medicine.

Possible Side Effects
Along with its desired effects, SPL7013 can cause some unwanted effects. Although not all of these effects are known, stomach pain and painful urination have been reported.

Drug and Food Interactions
A doctor should be notified of any other medications being taken, including prescription, nonprescription (over-the-counter), or herbal medications.

Clinical Trials
Click here to search ClinicalTrials.gov for trials that use SPL7013.

Manufacturer Information
SPL7013
  Starpharma Ltd
  PO Box 6535
  St. Kilda Road Central
  Melbourne, Victoria,  Australia
  61385322736
    
Updated October 6, 2008